Sawai Group Holdings Co., Ltd. · TSE:4887
Sawai — Q1 FY2026 Earnings Presentation
14 slides from Sawai's earnings presentation, Aug 10, 2026
Slide 1: Presentation Materials FY2026 Q1
Sawai Group Holdings Co., Ltd. Presentation Materials FY2026 Q1 August 10, 2026 4887, TSE Prime
Slide 2: Summary
Summary ▌Results for the First Three Months of FY2026 (Ended March 31,2027) ⚫ Revenue increased 4.3% YoY, core operating profit decreased 15.4% YoY, and operating profit decreased 29.0% YoY. Increased sales of products listed in FY2025 and FY2026 Sales decline in existing products due to NHI drug pr
Slide 3: Overview of Financial Results for Q1 FY2026
Overview of Financial Results for Q1 FY2026 ▌YoY change ⚫ Sales growth driven by strong sales of products listed in December 2025 and in June 2026 ⚫ Gross profit margin declined due to inventory valuation and disposal losses ⚫ Incurrence of R&D impairment losses (Unit: million yen) Full-Year Q1 FY20
Slide 4: Revenue by Product Listed Year
Revenue by Product Listed Year ⚫ Products listed in December 2025 performed strongly, led by Dapagliflozin ⚫ Products listed in June 2026 are also off to a strong start ⚫ Many products listed in or before 2023 saw revenue declines, mainly due to drug price revisions 51,622 (Unit: million yen) (YoY+4
Slide 5: Operating Profit Analysis
Operating Profit Analysis (Unit: million yen) (2,026) 460 • Increase in HR-related expenses, 1,093 including personnel costs • Consolidation of expenses of FrontAct 6,979 (911) (1,004) 4,953 • Increase in labor cost • Increase in depreciation cost (988) (122) (29) (525) • Impact of AG launch • Dispo
Slide 6: Reference Materials
Reference Materials
Slide 7: Strategies for Production Capacity Expansion
Strategies for Production Capacity Expansion ⚫ Impact on production from the Kumamoto Earthquake was minimal. ⚫ Scheduled launch of Step 2 at Daini Kyushu Factory new building in Dec 2026. ⚫ Proceeding with product transfers to the new building at Daini Kyushu Factory and Trust Pharmatech ⚫ Continue
Slide 8: Comparison of Sales Volume by Therapeutic Area
Comparison of Sales Volume by Therapeutic Area Q1 FY2025 Q1 FY2026 YoY change YoY change (value) Composition(volume) Composition(volume) (volume) Cardiovascular drugs 27.3% 27.2% +2.6% +1.4% Central nervous system drugs 15.9% 16.0% +3.4% +6.5% Gastro–intestinal drugs 15.6% 14.8% (2.9)% (3.5)% Other
Slide 9: Consolidated Financial Highlights 1
Consolidated Financial Highlights 1 ▌Consolidated Statements of Financial Position End of March 2026 End of June 2026 (Unit: billion yen) Total assets 359.9 Total assets 369.0 Current Current Liabilities Liabilities assets assets 200.3 203.7 191.3 181.4 v v Cash and cash v Cash and cash equivalents
Slide 10: Consolidated Financial Highlights 2
Consolidated Financial Highlights 2 ▌Consolidated Statements of Cash Flows (Unit: million yen) Q1 Q1 YoY FY2025 FY2026 Factors change results results • Profit before tax: +4,445 Operating CF (13,405) (427) +12,978 • Depreciation and amortization: +4,347 • Increase in inventory: (7,970) • Acquisition
Slide 11: Consolidated Financial Highlights 3
Consolidated Financial Highlights 3 ▌Key Income Statement Data (Unit: million yen) FY2025 FY2026 Results FY2026 Forecasts Results % of % of % of % of % of Q1 Q1 YoY H1 YoY H2 YoY Full-year YoY revenue revenue revenue revenue revenue Revenue 49,511 100.0% 51,622 100.0% +4.3% 101,000 100.0% +2.2% 107,
Slide 12: Consolidated Financial Highlights 4
Consolidated Financial Highlights 4 ▌Adjustment from Full Basis to Core Basis (Unit: million yen) Q1 FY2025 results Q1 FY2026 results Full basis Adjustment Core basis Full basis Adjustment Core basis Revenue 49,511 – 49,511 51,622 – 51,622 Cost of sales (34,074) 26 (34,047) (36,546) 98 (36,448) Gros
Slide 13: Consolidated Financial Data
Consolidated Financial Data ▌Sales and Production Volume (Unit: billion tablets) Q1 FY2025 Q1 FY2026 FY2026 full-year Results Results YoY change Forecasts YoY change Sales volume 4.2 4.3 +2.7% 17.6 +2.9% Production volume 3.9 4.4 +13.0% 18.0 +8.4% ▌Capital Investment, and Depreciation and Amortizati
Slide 14: Disclaimer
Disclaimer Forward–looking statements contained in this document are based on several assumptions and do not guarantee or assure the achievement of projected figures and the implementation of initiatives. Contact Sawai Group Holdings Co., Ltd. IR Group, Group Finance Department E-Mail ir@sawai.co.jp
Sawai Group Holdings — Q1 FY2026 Earnings Presentation on 6ix